Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Notice Of Intent Not A Part Of MCAC Executive Committee Meeting Agenda

This article was originally published in The Gray Sheet

Executive Summary

The executive committee of the Medicare Coverage Advisory Committee likely will not discuss at its June 6 meeting the Health Care Financing Administration's recently released "notice of intent" on Medicare coverage criteria.

You may also be interested in...



HCFA Criteria For Medicare Coverage Likely To Rekindle Cost Debate

The Health Care Financing Administration's "notice of intent" on Medicare coverage criteria proposes to consider cost as a factor in the agency's decision-making, but leaves the extent to which it would be used largely undefined.

MCAC Panel Process Concerns Derail Ratification Of Initial Coverage Opinions

Standard procedures for conducting Medicare Coverage Advisory Committee panel reviews must be developed if future panel recommendations are to hold any chance of ratification, several members of MCAC's Executive Committee maintained at a Dec. 8 meeting.

Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel